Navigation Links
Breast Cancer Patients and Families Stand Up To FDA
Date:6/24/2011

SILVER SPRING, Md., June 24, 2011 /PRNewswire/ -- Breast cancer patients and their families will rally together on Tuesday, June 28, at 7:00 am outside of the Federal Drug Administration (FDA).  At issue will be the FDA's final hearing to remove the anti-cancer drug Avastin from the approved medication list for treatment of late stage breast cancer, despite the FDA approving it in 2008 for use to treat breast cancer.

Terry Kalley, founder of the Freedom of Access to Medicines (FAMEDS), will lead the protest and then testify at the morning FDA hearing on behalf of his wife.  Following the FDA hearing, the group will make its way to Capitol Hill for congressional meetings, and wrap up the day with a media availability at 1:30 pm in 2103 Rayburn House Office Building.

"It is devastating enough to know that death will come early for these women from an incurable disease, but it is outrageous and unbelievably callous of FDA bureaucrats to compound this anguish," Kalley said.  "All we are asking for is for the federal government to stay out of our medical lives and allow my wife to continue taking this drug that is prolonging her life and the lives of many others."

At the June 28 hearing, the FDA will likely reverse its previous decision to allow Avastin to be used by breast cancer patients.  The FDA will likely cite dangerous side effects, but as Kalley pointed out, "For many breast cancer patients, including my wife, the most dangerous risk is the unavailability of Avastin."

Kalley warned that when government begins to pick winners and losers, a slippery slope towards rationing medications can happen. "Today, it's Avastin for metastatic breast cancer, tomorrow it could be the drug that your loved one needs to stay alive," he said.

He concluded with a call to action, saying "Attend our rally on the 28th, sign our online petition, and write your federal representatives and senators.  The lives of my wife and thousands of other women depend on it."

For more information on FAMEDS and the stories of breast cancer Avastin patients, go to www.fameds.org.


'/>"/>
SOURCE Freedom of Access to Medicines (FAMEDS)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... 23 janvier 2017  ResMed (NYSE : RMD), BMC (Pékin, ... ont annoncé aujourd,hui qu,ils se sont mis d,accord sur ... les parties. BMC et 3B seront autorisés à vendre ... à ResMed, et ResMed effectuera le paiement de la ... le litige de Floride entre les deux parties. Le ...
(Date:1/23/2017)... -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: ... agreement with the Children,s Hospital of Philadelphia ... US key opinion leader in the mitochondrial medicine field. ... Dr. ... research program, NVP015, in certain experimental disease models. The research ...
(Date:1/22/2017)... and ABU DHABI , Saudi Arabia ... from the US ... Hospital of the Future , at the World Economic ... of the future will be driven by big data and powered by artificial ... the panel of experts that discussed the ,Hospital of the Future, at the ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 24, 2017 , ... TopConsumerReviews.com ... for relieving premenstrual syndrome, or PMS . , Most women of child-bearing ... can include cramps, constipation, irritability, headaches, fatigue, and other discomfort. For some ...
(Date:1/24/2017)... ... ... Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the unexpected ... her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of published ... , Sharon shares that she started her spiritual journey later in life, but mentions, ...
(Date:1/24/2017)... ... ... “The Octagon of Spiritual Balances”: a guide for the Christian seeking ... published author, Pastor Bernard J. Weathers, pastor of Word of Faith Ministries, in Colonia, ... and a master degree in theology. , ““The Octagon of Spiritual Balances” exposes the ...
(Date:1/24/2017)... ... January 23, 2017 , ... CLICKco ... and espresso drink, announced its CLICK® Coffee Protein Drink is now available for ... Drink Mix has become popular among health-conscious consumers who love coffee but are ...
(Date:1/24/2017)... ... January 23, 2017 , ... United Nations Foundation ... of the Mexico City Policy, also known as the Global Gag Rule, last ... action, prohibits foreign non-governmental organizations from receiving any U.S. foreign assistance for family ...
Breaking Medicine News(10 mins):